Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
UNC Lineberger Comprehensive Cancer Center
With
Peregrine Pharmaceuticals
Subjects with measurable disease will be assessed for response after every 2 cycles of therapy using RECIST 1.1 criteria. In addition, progression free survival (PFS), overall survival (OS) and exploratory biomarkers, imaging, and thrombotic risk parameters will be evaluated.
Age
18–any
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
Greater than or equal to 18
Histologically or cytologically confirmed stage IV non-squamous NSCLC not previously treated with systemic chemotherapy
Evaluable disease by clinical or radiographic parameters
No history or concomitant malignancy
Adequate organ and marrow function
Female subjects with negative urine or serum pregnancy
ECOG must be 0 or 1
You may not be if
Squamous cell, small cell, or mixed histology
Known history of bleeding diathesis or coagulopathy
Cavitary tumors or tumors invading or abutting large blood vessels
Any history of thromboembolic events
Ongoing therapy with oral or parenteral anticoagulants
Major surgery within 4 weeks of Day 1 of treatment
